PHARMACEUTICAL 2016

Zynerba Pharmaceuticals Inc
Rank 50 of 295



PHARMACEUTICAL 2016

Zynerba Pharmaceuticals Inc
Rank 50 of 295

The relative strengths and weaknesses of Zynerba Pharmaceuticals Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Zynerba Pharmaceuticals Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 140% points.The greatest weakness of Zynerba Pharmaceuticals Inc is the variable Other Revenues, reducing the Economic Capital Ratio by 13% points.

The company's Economic Capital Ratio, given in the ranking table, is 376%, being 113% points above the market average of 263%.

Input Variable	Value in 1000 USD
Assets, Current	43,416
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	3,938
Liabilities, Non-Current	0
Other Assets	0.20
Other Compr. Net Income	0
Other Expenses	28
Other Liabilities	0
Other Net Income	7.4
Other Revenues	279
Property and Equipment	228
Research and Development	7,446
Selling, General and Administrative Expense	5,364

Output Variable	Value in 1000 USD
Assets	43,644
Liabilities	3,938
Expenses	12,838
Revenues	279
Stockholders Equity	39,706
Net Income	-12,551
Comprehensive Net Income	-12,551
BaseVar	30,353
ECR before LimitedLiability	311%
Economic Capital Ratio	376%